RT Journal Article
T1 Myocarditis Related to COVID-19 and SARS-CoV-2 Vaccination.
A1 Molina-Ramos, Ana I
A1 Gómez-Moyano, Elisabeth
A1 Rodríguez-Capitán, Jorge
A1 Angullo-Gómez, María
A1 Gallardo-Jiménez, Patricia
A1 Pérez de Pedro, Iván
A1 Valiente de Santis, Lucía
A1 Pérez-Villardón, Beatriz
A1 Piñero-Uribe, Isabel
A1 Mora-Robles, Javier
A1 Becerra-Muñoz, Víctor Manuel
A1 Jiménez-Navarro, Manuel
K1 COVID-19
K1 mRNA vaccines
K1 myocarditis
AB The coronavirus disease of 2019 (COVID-19) has been a cause of significant morbidity and mortality worldwide. Among the short- and long-term consequences of COVID-19, myocarditis is a disease to be taken into consideration. Myocarditis, in general, is related to a poor prognosis. However, the epidemiology and prognosis of myocarditis related to COVID-19 are currently unknown. While vaccination against COVID-19 is of great benefit at a public health level, the risk of myocarditis should be considered in the context of the global benefits of vaccination. In this narrative review, we will summarize the etiopathogenic bases, the epidemiology, the clinical manifestations, the course, diagnosis, prognosis, and the treatment of myocarditis related to SARS-CoV-2, as well as myocarditis secondary to mRNA vaccines.
SN 2077-0383
YR 2022
FD 2022-11-26
LK http://hdl.handle.net/10668/21365
UL http://hdl.handle.net/10668/21365
LA en
DS RISalud
RD Apr 19, 2025